Clinical Trial Update: Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab for ovarian squamous cell carcinoma is currently active but not recruiting. The study is sponsored by Niigata University Medical …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Niigata University Medical & Dental Hospital | Conditions: Ovarian Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING